A case of probable cerebral amyloid angiopathy

Authors

  • N. Hristova UHATNP „St. Naum”
  • N. Kamenova UHATNP „St. Naum”
  • O. Burgazlieva UHATNP „St. Naum”
  • S. Ivanova UHATNP "St.Naum"; Medical university – Sofia
  • N. Topalov UHATNP "St.Naum"; Medical university – Sofia

Keywords:

Cerebral amyloid angiopathy, Modified Boston criteria, MRI – SWI sequence

Abstract

Cerebral amyloid angiopathy is a cerebrovascular disease caused by β-amyloid deposition in cerebral vessels – arteries, arterioles and capillaries. The pathology is common among elderly patients and is associated with an increased risk of intracerebral bleeding. Cerebral amyloid angiopathy (CAA) can be divided into sporadic (spontaneous) and familial forms. The diagnosis is based on neurophysiological examination, brain imaging techniques (mainly MRI SWI sequence) and usage of Modified Boston Criteria from 2010. Aside from fewer described cases in our literature (1) the disease is still unfamiliar and requires multidisplinary approach.

References

Milanov, I., Dokova, Ĭ., Topalov, N. Klinichen sluchaĭ na patsient s tserebralna amiloidna angiopatiya. Bŭlgarska nevrologiya, 2014, 103-104.

Attems, J., Lintner, F., Jellinger, K. Amyloid β peptide 1-42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology. Acta Neuropathologica, 2004, 107, 4, 283-291.

Eng, J., Frosch, M., Choi, K., Rebeck, G., Greenberg, S. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol., 2004, 55, 2, 250-256.

Caetano, A., Ladeira, F., Barbosa, R., Calado, S., Viana-Baptista, M. Cerebral amyloid angiopathy – The modified Boston criteria in clinical practice. Journal of the Neurological Sciences, 2018, 384, 55-57.

Akter, M., Hirai, T., Hiai, Y., Kitajima, M., Komi, M., Murakami, R., Fukuoka, H., et al. Detection of Hemorrhagic Hypointense Foci in the Brain on Susceptibility-Weighted Imaging. Academic Radiology, 2007, 14, 9, 1011-1019.

Yamada, M. Cerebral amyloid angiopathy: An overview. Neuropathology, 2000, 20, 1, 8-22.

Zhang, H., Linn, J., Bruckmann, H., Greenberg, S. Prevalence of Superficial Siderosis in Patients with Cerebral Amyloid Angiopathy. Neurology, 2010, 75, 17, 1571-1571.

Stanton, J., Chandratheva, A., Wilson, D., Hostettler, I. Clinical features distinguish cerebral amyloid angiopathy-associated convexity subarachnoid haemorrhage from suspected TIA. J. Neurol., 2020, 267, 1, 133-137.

Yamada, M. Brain hemorrhages in cerebral amyloid angiopathy. Semin Thromb Hemost., 2013, 39, 955-962.

Landen, J., Zhao, Q., Cohen, S., Borrie, M., Woodward, M., Billing, C. Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease. Clinical Neuropharmacology, 2013, 36, 1, 14-23.

Bales, K., O’Neill, S., Pozdnyakov, N., Pan, F., Caouette, D. Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity, 2016, 139, 2, 563-577.

Downloads

Published

01.09.2020

How to Cite

Hristova, N., Kamenova, N., Burgazlieva, O., Ivanova, S., & Topalov, N. (2020). A case of probable cerebral amyloid angiopathy. Movement Disorders Bulgaria, 17(1), 53–56. Retrieved from https://www.multiplesclerosis-bg.com/journal/index.php/md/article/view/37

Issue

Vol. 17 No. 1 (2020): Movement Disorders Bulgaria

Section

CASE REPORT

License

Copyright (c) 2020 N. Hristova, N. Kamenova, O. Burgazlieva, S. Ivanova, N. Topalov

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.